Oxford Vaccine Group

Vaccine research group; engaged in data-driven and AI-assisted vaccine research.

Epistemic Overview

About the Institute

A world-renowned clinical research group at the University of Oxford, which increasingly uses data-driven and AI-assisted methods.

Key Facts

Founded

1994

Director / President

Prof Sir Andrew Pollard (Director)

Category

Research Group / Clinical

Research Domains

health
clinical research

Timeline

1994

The Oxford Vaccine Group (OVG) is founded within the Department of Paediatrics by Professor Richard Moxon.

c. 2000

Prof. Andrew Pollard (current Director) joins the group and expands its work into adult and paediatric vaccine trials.

c. 2005

OVG establishes itself as a world-leading centre for meningitis vaccine development.

Jan 2020

OVG partners with the Jenner Institute to design a vaccine candidate for a novel coronavirus, SARS-CoV-2.

Apr 2020

OVG begins Phase 1 human trials of the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine.

Dec 2020

The Oxford–AstraZeneca vaccine is approved for use in the UK, marking a pivotal moment in the pandemic.

2023

The group leverages data science and AI-assisted analysis for its ongoing research into new vaccines (e.g., for typhoid, malaria).

Influential Papers / Notable Research

  • Led the development and clinical trials of the ChAdOx1 nCoV-19 (Oxford–AstraZeneca) vaccine.

  • Uses data science and ML to analyze complex trial data and model vaccine efficacy.

  • Research on using data-driven approaches to predict immune responses and optimize vaccine design.